Company Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs.
Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.
The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
| Country | United States |
| IPO Date | Nov 14, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 486 |
| CEO | Thane Wettig |
Contact Details
Address: 409 Illinois Street San Francisco, California 94158 United States | |
| Phone | 415-978-1200 |
| Website | fibrogen.com |
Stock Details
| Ticker Symbol | FGEN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000921299 |
| CUSIP Number | 31572Q808 |
| ISIN Number | US31572Q8087 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Thane Wettig | Chief Executive Officer and Director |
| Juan Graham | Senior Vice President and Chief Financial Officer |
| Christine L. Chung | Senior Vice President of China Operations |
| Dr. Barry A. Berkowitz Ph.D. | Founder |
| Dr. John J. Hunter Ph.D. | Chief Scientific Officer |
| David DeLucia | Vice President of Corporate FP&A and Investor Relations |
| Michael D. Lowenstein J.D., Ph.D. | Chief Legal Officer |
| Tricia Stewart | Chief People Officer |
| Kirk A. Christoffersen MBA | Chief Business Officer |
| Dr. Rahul Rajan Kaushik Ph.D. | Senior Vice President of Pharmaceutical Development, Technical Operations and Manufacturing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2024 | ARS | Filing |
| Apr 24, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 24, 2024 | DEF 14A | Other definitive proxy statements |
| Feb 26, 2024 | 10-K | Annual Report |
| Feb 26, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 26, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |